ACHL — Achilles Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $52.20m
- -$87.94m
- 19
- 51
- 74
- 45
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 10.7 | 97.6 | 178 | 266 | 173 |
Net Total Receivables | 0.001 | 0.327 | 1.13 | 0.65 | 0.771 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13.4 | 103 | 188 | 285 | 197 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.583 | 2.11 | 28.1 | 28.8 | 20.5 |
Other Long Term Assets | |||||
Total Assets | 14 | 105 | 219 | 317 | 220 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.29 | 3.86 | 16.6 | 19.1 | 18 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.29 | 3.86 | 29.5 | 27.6 | 23.3 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 12.7 | 101 | 189 | 290 | 197 |
Total Liabilities & Shareholders' Equity | 14 | 105 | 219 | 317 | 220 |
Total Common Shares Outstanding |